• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SIGA Technologies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/10/26 4:05:24 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SIGA alert in real time by email
    false000101008600010100862026-06-092026-06-09

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15 (d) OF
    THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): June 9, 2026

    SIGA TECHNOLOGIES, INC.

    (Exact name of registrant as specified in its charter)

    Delaware
    0-23047
    13-3864870
    (State or other jurisdiction of incorporation or organization)
    (Commission file number)
    (I.R.S. employer identification no.)

    31 East 62nd Street
    New York, New York

    10065
    (Address of principal executive offices)

    (Zip code)

    Registrant’s telephone number, including area code: (212) 672-9100

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
    Trading Symbol(s)
    Name of each exchange on which
    registered
    common stock, $.0001 par value
    SIGA
    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.02.
    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

    SIGA Technologies, Inc. (the “Company”) held its 2026 annual meeting of stockholders on June 9, 2026 (the “Annual Meeting”). As further described under Item 5.07 below, at the Annual Meeting, the Company’s stockholders approved an amendment (“Plan Amendment”) to the Company’s Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”), to increase the aggregate number of shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), authorized for issuance under the 2010 Plan by 6,500,000 shares.

    A summary of the Plan Amendment is contained in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission (“SEC”) on April 28, 2026 (the “Proxy Statement”) and the Supplement to the Proxy Statement filed with the SEC on May 8, 2026 (the “Supplement”), in connection with the Annual Meeting under the heading “PROPOSAL 4: APPROVAL OF AN AMENDMENT TO THE AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR ISSUANCE UNDER THE PLAN BY 6,500,000 SHARES” and are incorporated herein by reference.

    The foregoing summary is not intended to be complete and is qualified in its entirety by reference to the full text of the 2010 Plan and the Plan Amendment, copies of which are attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 5.02.

    Item 5.07.
    Submission of Matters to a Vote of Security Holders.

    At the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) of the Company held on June 9, 2026, stockholders representing 62,436,105 shares of common stock, or 87.05% of the shares of common stock outstanding as of the April 17, 2026, record date, attended or were represented by proxy. The items listed below were submitted to a vote of the stockholders who attended or were represented by proxy, and were entitled to vote at, the 2026 Annual Meeting. Final voting results are shown below.

    At the 2026 Annual Meeting, the stockholders of the Company (i) elected eight director nominees to hold office until the 2026 Annual Meeting of Stockholders of the Company and their successors are elected and qualified and until their earlier resignation or removal, (ii) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, (iii) approved the non-binding advisory resolution on the compensation of the Company’s named executive officers, and (iv) approved an amendment to the 2010 Plan to increase the maximum number of shares of Common Stock authorized for issuance under the 2010 Plan from 8,500,000 shares to 15,000,000 shares. Set forth below are the final voting results for the four proposals submitted to a vote of the stockholders.


    (1) Election of the following individuals to hold office as directors of the Company for terms of one year.

    Name
    For
    Withheld



    Jaymie A. Durnan
    45,259,891
    5,974,743



    Harold E. Ford, Jr
    50,828,584
    406,050



    General John M. Keane
    50,710,136
    524,498



    Joseph W. Marshall, III
    45,722,184
    5,512,450



    Gary J. Nabel, M.D., Ph.D.
    46,871,987
    4,362,647



    Julian Nemirovsky
    49,445,175
    1,789,459



    Diem Nguyen, Ph.D., MBA
    49,884,604
    1,350,030



    Holly L. Phillips, M.D.
    48,612,659
    2,621,975



    (2) Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.

    For
    Against
    Abstain
    62,040,317
    343,043
    52,745



    (3) Approval of the non-binding advisory resolution on the compensation of the Company’s named executive officers.

    For
    Against
    Abstain
    48,744,042
    2,404,456
    86,136



    (4) Approval of an amendment to the 2010 Plan to increase the maximum number of shares of Common Stock authorized for issuance under the 2010 Plan from 8,500,000 shares to 15,000,000 shares.

    For
    Against
    Abstain
    38,823,234
    12,390,841
    20,559

    With respect Proposals (1), (2) and (4) there were 11,201,471 broker “non votes.”


    Item 9.01.
    Financial Statements and Exhibits.

    (d)
    The following exhibits are included in this report:

    Exhibit
    No.

    Description



    10.1

    SIGA Technologies, Inc. Amended and Restated 2010 Stock Incentive Plan and its Amendment



    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    SIGA TECHNOLOGIES, INC.



    By:
    /s/ Daniel J. Luckshire

    Name: Daniel J. Luckshire

    Title: Chief Financial Officer


    Date: June 10, 2026




    Get the next $SIGA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SIGA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SIGA
    SEC Filings

    View All

    SIGA Technologies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    6/10/26 4:05:24 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by SIGA Technologies Inc.

    DEFA14A - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    5/8/26 4:01:30 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by SIGA Technologies Inc.

    10-Q - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    5/7/26 4:48:48 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

    On Track to Deliver $13 Million of Oral TPOXX to an International Customer in Second QuarterExpect to Deliver $26 Million of IV TPOXX to the U.S. Government Strategic National Stockpile by End of the Third Quarter Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2026. "Consistent with our long-term strategy, we expect to deliver more than $35 million of oral and IV TPOXX to a combination of the U.S. Government and an international customer across the second and third quarters of 2026,"

    5/7/26 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results

    NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 7, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738

    4/30/26 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Declares Special Cash Dividend of $0.60 Per Share

    NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. The amount of this dividend is consistent with the level of the special dividend declared in April 2025. The dividend is payable on April 23, 2026, to shareholders of record at the close of business on April 7, 2026. "Today's announcement of a special cash dividend reflects the strength of our balance sheet and focus on maximizing shareholder value," said Diem Nguyen, Chief Executive Officer. "We remain committed to executing our st

    3/26/26 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Marshall Joseph W Iii converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 7% to 246,523 units (SEC Form 4) (withholding tax)

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    6/10/26 9:33:06 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Keane John M converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39) (SEC Form 4) to satisfy withholding obligation

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    6/10/26 9:30:33 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ford Harold Eugene Jr. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 55% to 47,538 units (SEC Form 4) (withholding obligation)

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    6/10/26 9:27:56 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Leadership Updates

    Live Leadership Updates

    View All

    SIGA Appoints Retired General John M. Keane to its Board of Directors

    NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army General John "Jack" Keane to its Board of Directors, effective immediately. General Keane, a retired four-star general, completed 37 years of public service in December 2003, culminating with his appointment as acting Chief of Staff and Vice Chief of Staff of the U.S. Army from 1999 to 2003. He is a foreign policy and national security expert who serves as an advisor to presidents, cabinet officials, members of congress, international leaders, CEOs, and business leaders. He also provide

    3/18/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Names Larry Miller General Counsel

    NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. "With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving SIGA's continued success and growth strategies forward," said Diem Nguyen, Chief Executive Officer.  "Larry will be instrumental in helping us expand our reach on a global scale and maximize the ben

    3/25/24 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

    NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company's Board of Directors. SIGA's current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024. "The appointment of Diem Nguyen as our new CEO marks a significant milestone for SIGA as we continue to expand our partnerships with governments across the world in global health security initiatives and medical countermeasure preparedness," said Josep

    1/22/24 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SIGA Technologies Inc.

    SC 13G - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    2/1/24 3:54:12 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by SIGA Technologies Inc. (Amendment)

    SC 13G/A - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    2/14/23 4:42:47 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SIGA Technologies Inc.

    SC 13G - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    6/24/22 4:05:38 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Financials

    Live finance-specific insights

    View All

    SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

    On Track to Deliver $13 Million of Oral TPOXX to an International Customer in Second QuarterExpect to Deliver $26 Million of IV TPOXX to the U.S. Government Strategic National Stockpile by End of the Third Quarter Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2026. "Consistent with our long-term strategy, we expect to deliver more than $35 million of oral and IV TPOXX to a combination of the U.S. Government and an international customer across the second and third quarters of 2026,"

    5/7/26 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results

    NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 7, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738

    4/30/26 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Declares Special Cash Dividend of $0.60 Per Share

    NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. The amount of this dividend is consistent with the level of the special dividend declared in April 2025. The dividend is payable on April 23, 2026, to shareholders of record at the close of business on April 7, 2026. "Today's announcement of a special cash dividend reflects the strength of our balance sheet and focus on maximizing shareholder value," said Diem Nguyen, Chief Executive Officer. "We remain committed to executing our st

    3/26/26 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care